Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Background The combination of verteporfin photodynamic therapy (PDT) and anti-angiogenics has been shown to be safe and efficacious in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The purpose of this study is to demonstrate long-term prevention of vision loss and improvement in best-corrected visual acuity (BCVA) after treatment with one-time reduced-fluence-rate PDT followed by administration of ranibizumab on a variable dosing regimen over 24 months in patients with neovascular AMD. Secondary outcome measures included the change in central macular thickness (CMT), reinjection frequency, and safety. Methods This prospective, nonrandomized, open-label, single-center study enrolled 27 consecutive patients (27 eyes) presenting at the Leuven University Eye Hospital with previously untreated, active neovascular AMD between September 2006 and January 2007. All patients were treated with one-time, reduced-fluence-rate verteporfin PDT, followed by intravitreal ranibizumab 0.5 mg on the same day. A second and third ranibizumab injection were given at weeks 4 and 8, respectively, after which patients were followed up monthly for 24 months. Additional treatment with ranibizumab was administered to eyes with active neovascularization as indicated clinically and on imaging studies. Retreatment was based on the following criteria: (1) presence of subretinal fluid (SRF), intraretinal edema or sub-retinal pigment epithelial fluid,…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another series reported no associations between CFH and ARMS2/HTRA1 variants and the combination therapy using anti-VEGF and PDT [53].”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [53]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 41 · Cited by 31
Metadata
- Authors
- Spielberg, L., & Leys, A.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Corresponding author
- Spielberg, Leigh
- Venue
- Graefe's Archive for Clinical and Experimental Ophthalmology
- Published
- 2010-03-04
- Volume
- 248
- Issue
- 7
- Pages
- 943-956
- ISSN
- 0721-832X (ISSN-L)
- 1435-702X
- OpenAlex
- W2064939547
- Cited by
- 31
- References
- 41
- Citations by year
- 2024: 2 · 2022: 1 · 2021: 2 · 2020: 2 · 2018: 1 · 2016: 3 · 2015: 4 · 2014: 4 · 2013: 3 · 2012: 6
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Graefe s Archive for Clinical and Experimental Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neovascular age-related macular degeneration, choroidal neovascularization, ranibizumab, verteporfin photodynamic therapy, anti-VEGF therapy, best-corrected visual acuity, central macular thickness, occult CNV, subretinal fluid
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Aged, 80 and over, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Macular Degeneration, Male, Middle Aged, Photochemotherapy, Porphyrins, Prospective Studies, Time Factors, Visual Acuity, Treatment Outcome, Photosensitizing Agents, Angiogenesis Inhibitors, Tomography, Optical Coherence, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. https://app.cochat.ai/papers/10.1007/s00417-009-1256-6
- The paper
- Spielberg, L., & Leys, A. (2010). Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-009-1256-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.